Medical News |
- Attentional biases toward emotion help characterize bipolar disorder
- Daclatasvir–sofosbuvir combo effective in chronic HCV infection
- Novel <i>HER2</i> mutation identified in familial lung adenocarcinomas
- Immunotherapy maintenance shows promise in NSCLC
- Novel <i>HER2</i> mutation identified in familial lung adenocarcinomas
- Immunotherapy maintenance shows promise in NSCLC
- Attentional biases toward emotion help characterize bipolar disorder
- Psychosis risk factors have limited predictive power
- Psychosis risk factors have limited predictive power
- Etoposide plus cisplatin remains best for limited-stage SCLC
- Etoposide plus cisplatin remains best for limited-stage SCLC
- Etoposide plus cisplatin remains best for limited-stage SCLC
| Attentional biases toward emotion help characterize bipolar disorder Posted: 23 Jan 2014 04:00 PM PST Attentional biases toward emotional images are a key feature of bipolar disorder and may contribute to increased vulnerability and continued maintenance of the condition, researchers report. |
| Daclatasvir–sofosbuvir combo effective in chronic HCV infection Posted: 23 Jan 2014 04:00 PM PST Research shows that the combination of daclatasvir and sofosbuvir leads to high rates of sustained virologic response in patients with chronic hepatitis C virus infection, including those who have not responded to previous therapy. |
| Novel <i>HER2</i> mutation identified in familial lung adenocarcinomas Posted: 23 Jan 2014 04:00 PM PST Researchers have identified a novel germline mutation in the transmembrane domain of the human epidermal growth factor receptor 2 gene in familial lung adenocarcinomas. |
| Immunotherapy maintenance shows promise in NSCLC Posted: 23 Jan 2014 04:00 PM PST Results from a phase III trial have shown that tecemotide is no more effective than placebo as maintenance therapy in patients with non-small-cell lung cancer. |
| Novel <i>HER2</i> mutation identified in familial lung adenocarcinomas Posted: 23 Jan 2014 04:00 PM PST Researchers have identified a novel germline mutation in the transmembrane domain of the human epidermal growth factor receptor 2 gene in familial lung adenocarcinomas. |
| Immunotherapy maintenance shows promise in NSCLC Posted: 23 Jan 2014 04:00 PM PST Results from a phase III trial have shown that tecemotide is no more effective than placebo as maintenance therapy in patients with non-small-cell lung cancer. |
| Attentional biases toward emotion help characterize bipolar disorder Posted: 23 Jan 2014 04:00 PM PST Attentional biases toward emotional images are a key feature of bipolar disorder and may contribute to increased vulnerability and continued maintenance of the condition, researchers report. |
| Psychosis risk factors have limited predictive power Posted: 23 Jan 2014 04:00 PM PST Factors known to be linked to schizophrenia risk have little predictive power at either the individual or population level, report researchers. |
| Psychosis risk factors have limited predictive power Posted: 23 Jan 2014 04:00 PM PST Factors known to be linked to schizophrenia risk have little predictive power at either the individual or population level, report researchers. |
| Etoposide plus cisplatin remains best for limited-stage SCLC Posted: 22 Jan 2014 04:00 PM PST Etoposide plus cisplatin, given alongside accelerated hyperfractionated thoracic radiotherapy, remains the gold standard regimen for patients with limited-stage small-cell lung cancer, Japanese researchers say. |
| Etoposide plus cisplatin remains best for limited-stage SCLC Posted: 22 Jan 2014 04:00 PM PST Etoposide plus cisplatin, given alongside accelerated hyperfractionated thoracic radiotherapy, remains the gold standard regimen for patients with limited-stage small-cell lung cancer, Japanese researchers say. |
| Etoposide plus cisplatin remains best for limited-stage SCLC Posted: 22 Jan 2014 04:00 PM PST Etoposide plus cisplatin, given alongside accelerated hyperfractionated thoracic radiotherapy, remains the gold standard regimen for patients with limited-stage small-cell lung cancer, Japanese researchers say. |
| You are subscribed to email updates from MedWire Medical News Combined Feed To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google Inc., 20 West Kinzie, Chicago IL USA 60610 | |
No comments:
Post a Comment